查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1703286

小分子創新 CDMO 市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、階段類型、客戶類型、治療領域、地區和競爭細分，2020-2030 年預測

Small Molecule Innovator CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Stage Type, By Customer Type, By Therapeutic Area, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球小分子創新合約開發和製造組織 (CDMO) 市場價值為 482.6 億美元，預計到 2030 年將達到 722.6 億美元，預測期內年複合成長率(CAGR) 為 6.96%。

市場概覽
預測期 2026-2030
2024年市場規模 482.6億美元
2030年市場規模 722.6億美元
2025-2030 年複合年成長率 6.96%
成長最快的領域 小分子API
最大的市場 北美洲

該市場是製藥和生物製藥行業的重要組成部分，提供藥物開發和製造方面的重要服務。小分子－用作活性藥物成分（API）的低分子量化合物－廣泛用於生產各種治療藥物。專門從事小分子的 CDMO 提供端到端解決方案，包括藥物開發、製程最佳化、擴大規模、製造和監管支援。

小分子創新者 CDMO 是專業實體，透過從早期開發到小分子 API 和成品藥品商業生產的綜合服務為製藥和生物技術公司提供支援。

市場成長動力

外包趨勢日益增強

小分子創新CDMO市場外包趨勢日益成長，這是製藥和生物技術公司尋求最佳化藥物開發和資源配置的策略性反應。外包使公司能夠提高營運效率、利用專業知識並加快產品上市時間。

與 CDMO 合作具有顯著的優勢。這些組織帶來了配方開發、製程最佳化、分析測試和法規遵循的深入知識，這些能力對於小分子療法的成功開發至關重要。透過外包這些功能，製藥創新者可以避免與建立內部能力相關的大量投資，同時仍可受益於尖端技術和成熟的流程。

此外，現代藥物開發的複雜性和多學科性要求敏捷性和監管敏銳性，而 CDMO 完全有能力提供這些品質。這些合作關係也使創新公司能夠專注於其核心優勢，例如研究和臨床開發，同時將製造和營運任務委託給經驗豐富的合作夥伴。

市場挑戰

智慧財產權（IP）保護

小分子創新 CDMO 市場面臨的關鍵挑戰是智慧財產權的保護。創新公司通常會在研發方面投入巨資，以創造新型化合物和專有製造流程。在建立CDMO合作夥伴關係時，他們必須分享機密資料，包括化學結構、合成方法和分析技術。

這種交換引入了與 IP 外洩或未經授權揭露相關的風險。為了緩解這些擔憂，公司通常會實施嚴格的保密協議（例如，保密協議或 NDA），概述專有資訊的共享、使用和保護條款。這些法律保障對於在整個開發生命週期中維持信任和確保競爭優勢至關重要。

市場趨勢

個人化醫療和利基療法的出現

個人化醫療和利基療法正在重塑製藥業格局，它們專注於根據個別患者特徵或針對具有獨特健康狀況的特定人群制定客製化治療策略。

在此背景下，小分子創新者CDMO市場扮演越來越重要的角色。個人化醫療旨在透過調整治療策略以適應患者的遺傳特徵、生活方式和疾病特異性生物標記來增強治療效果。創新公司正在開發針對這些獨特標記的小分子藥物，以提高療效並減少副作用。

CDMO 在將這些療法推向市場方面發揮著重要作用。他們在分子生物學、藥物基因組學和分析化學方面的專業知識使他們能夠支持客製化治療的開發和製造。這些能力對於確保個人化治療所需的精確度、可擴展性和法規遵循至關重要。

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球小分子創新公司 CDMO 市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品（小分子 API、小分子藥物產品）
    • 依階段類型（臨床前、臨床、商業化）
    • 依客戶類型（製藥、生技）
    • 依治療領域（心血管疾病、腫瘤學、呼吸系統疾病、神經病學、代謝性疾病、傳染病、其他）
    • 按地區（北美、歐洲、亞太、南美、中東和非洲）
    • 按公司分類（2024）
  • 產品市場圖
    • 按產品
    • 按階段類型
    • 依客戶類型
    • 按治療領域
    • 按地區

第6章：北美小分子創新公司 CDMO 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲小分子創新公司 CDMO 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太小分子創新公司 CDMO 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第9章：南美洲小分子創新公司 CDMO 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲小分子創新 CDMO 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購
  • 產品開發
  • 最新動態

第 13 章：臨床試驗分析

第 14 章：競爭格局

  • Lonza Group AG
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials (As Reported)
  • Recent Developments
  • Key Personnel Details
  • SWOT Analysis
  • Thermo Fisher Scientific Inc
  • Cambrex Corporation
  • Catalent, Inc
  • Siegfried Holding AG
  • Recipharm AB
  • Corden Pharma GmbH
  • Boehringer Ingelheim GmbH
  • Piramal Pharma Solutions
  • LABCORP HOLDINGS INC.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17094

Global Small Molecule Innovator Contract Development and Manufacturing Organization (CDMO) market was valued at USD 48.26 billion in 2024 and is projected to reach USD 72.26 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.96% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 48.26 Billion
Market Size 2030USD 72.26 Billion
CAGR 2025-20306.96%
Fastest Growing SegmentSmall Molecule API
Largest MarketNorth America

This market forms a vital part of the pharmaceutical and biopharmaceutical industries, offering essential services in drug development and manufacturing. Small molecules-low molecular weight compounds used as active pharmaceutical ingredients (APIs)-are widely employed in the production of various therapeutic drugs. CDMOs specializing in small molecules provide end-to-end solutions, including drug development, process optimization, scale-up, manufacturing, and regulatory support.

Small Molecule Innovator CDMOs are specialized entities that support pharmaceutical and biotech companies through comprehensive services that span from early-stage development to commercial production of small molecule APIs and finished drug products.

Market Growth Drivers

Increasing Trend Toward Outsourcing

The growing trend of outsourcing in the Small Molecule Innovator CDMO market is a strategic response by pharmaceutical and biotechnology companies seeking to optimize drug development and resource allocation. Outsourcing enables firms to improve operational efficiency, leverage specialized expertise, and accelerate time-to-market.

Partnering with CDMOs offers significant advantages. These organizations bring in-depth knowledge of formulation development, process optimization, analytical testing, and regulatory compliance-capabilities critical to the successful development of small molecule therapeutics. By outsourcing these functions, pharmaceutical innovators can avoid the substantial investments associated with building in-house capabilities, while still benefiting from cutting-edge technologies and proven processes.

Moreover, the complex and multidisciplinary nature of modern drug development requires agility and regulatory acumen-qualities that CDMOs are well-equipped to provide. These partnerships also allow innovator companies to maintain focus on their core strengths, such as research and clinical development, while entrusting manufacturing and operational tasks to experienced partners.

Market Challenges

Intellectual Property (IP) Protection

A key challenge in the Small Molecule Innovator CDMO market is the safeguarding of intellectual property. Innovator companies often invest heavily in R&D to create novel compounds and proprietary manufacturing processes. When entering into CDMO partnerships, they must share confidential data, including chemical structures, synthetic methodologies, and analytical techniques.

This exchange introduces risks related to IP leakage or unauthorized disclosure. To mitigate these concerns, companies typically implement strict confidentiality agreements (e.g., Non-Disclosure Agreements or NDAs) outlining terms for the sharing, usage, and protection of proprietary information. These legal safeguards are critical to maintaining trust and securing competitive advantages throughout the development lifecycle.

Market Trends

Emergence of Personalized Medicine and Niche Therapies

Personalized medicine and niche therapies are reshaping the pharmaceutical landscape by focusing on customized treatment strategies based on individual patient profiles or targeting specific populations with unique health conditions.

In this context, the Small Molecule Innovator CDMO market is playing an increasingly vital role. Personalized medicine seeks to enhance therapeutic outcomes by aligning treatment strategies with a patient's genetic characteristics, lifestyle, and disease-specific biomarkers. Innovator companies are developing small molecule drugs that target these unique markers, offering improved efficacy and reduced side effects.

CDMOs are instrumental in bringing these therapies to market. Their expertise in molecular biology, pharmacogenomics, and analytical chemistry enables them to support the development and manufacturing of tailored treatments. These capabilities are essential to ensuring the precision, scalability, and regulatory compliance required for personalized therapies.

Key Market Players

Lonza Group AG

Thermo Fisher Scientific Inc

Cambrex Corporation

Catalent, Inc

Siegfried Holding AG

Recipharm AB

Corden Pharma GmbH

Boehringer Ingelheim GmbH

Piramal Pharma Solutions

LABCORP HOLDINGS INC.

Report Scope:

In this report, the Global Small Molecule Innovator CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small Molecule Innovator CDMO Market, By Product:

Small Molecule API

Small Molecule Drug Product

Small Molecule Innovator CDMO Market, By Stage Type:

Preclinical

Clinical

Commercial

Small Molecule Innovator CDMO Market, By Customer Type:

Pharmaceutical

Biotechnology

Small Molecule Innovator CDMO Market, By Therapeutic Area:

Cardiovascular disease

Oncology

Respiratory disorders

Neurology

Metabolic disorders

Infectious disease

Others

Small Molecule Innovator CDMO Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • UAE
  • Saudi Arabia
  • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small Molecule Innovator CDMO Market.

Available Customizations:

Global Small Molecule Innovator CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Small Molecule Innovator CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Small Molecule API, Small Molecule Drug Product)
    • 5.2.2. By Stage Type (Preclinical, Clinical, Commercial)
    • 5.2.3. By Customer Type (Pharmaceutical, Biotechnology)
    • 5.2.4. By Therapeutic Area (Cardiovascular disease, Oncology, Respiratory disorders, Neurology, Metabolic disorders, Infectious disease, Others)
    • 5.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.6. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Product
    • 5.3.2. By Stage Type
    • 5.3.3. By Customer Type
    • 5.3.4. By Therapeutic Area
    • 5.3.5. By Region

6. North America Small Molecule Innovator CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Stage Type
    • 6.2.3. By Customer Type
    • 6.2.4. By Therapeutic Area
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Small Molecule Innovator CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Stage Type
        • 6.3.1.2.3. By Customer Type
        • 6.3.1.2.4. By Therapeutic Area
    • 6.3.2. Canada Small Molecule Innovator CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Stage Type
        • 6.3.2.2.3. By Customer Type
        • 6.3.2.2.4. By Therapeutic Area
    • 6.3.3. Mexico Small Molecule Innovator CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Stage Type
        • 6.3.3.2.3. By Customer Type
        • 6.3.3.2.4. By Therapeutic Area

7. Europe Small Molecule Innovator CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Stage Type
    • 7.2.3. By Customer Type
    • 7.2.4. By Therapeutic Area
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Small Molecule Innovator CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Stage Type
        • 7.3.1.2.3. By Customer Type
        • 7.3.1.2.4. By Therapeutic Area
    • 7.3.2. France Small Molecule Innovator CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Stage Type
        • 7.3.2.2.3. By Customer Type
        • 7.3.2.2.4. By Therapeutic Area
    • 7.3.3. United Kingdom Small Molecule Innovator CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Stage Type
        • 7.3.3.2.3. By Customer Type
        • 7.3.3.2.4. By Therapeutic Area
    • 7.3.4. Italy Small Molecule Innovator CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Stage Type
        • 7.3.4.2.3. By Customer Type
        • 7.3.4.2.4. By Therapeutic Area
    • 7.3.5. Spain Small Molecule Innovator CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Stage Type
        • 7.3.5.2.3. By Customer Type
        • 7.3.5.2.4. By Therapeutic Area

8. Asia-Pacific Small Molecule Innovator CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Stage Type
    • 8.2.3. By Customer Type
    • 8.2.4. By Therapeutic Area
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Small Molecule Innovator CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Stage Type
        • 8.3.1.2.3. By Customer Type
        • 8.3.1.2.4. By Therapeutic Area
    • 8.3.2. Japan Small Molecule Innovator CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Stage Type
        • 8.3.2.2.3. By Customer Type
        • 8.3.2.2.4. By Therapeutic Area
    • 8.3.3. India Small Molecule Innovator CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Stage Type
        • 8.3.3.2.3. By Customer Type
        • 8.3.3.2.4. By Therapeutic Area
    • 8.3.4. South Korea Small Molecule Innovator CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Stage Type
        • 8.3.4.2.3. By Customer Type
        • 8.3.4.2.4. By Therapeutic Area
    • 8.3.5. Australia Small Molecule Innovator CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Stage Type
        • 8.3.5.2.3. By Customer Type
        • 8.3.5.2.4. By Therapeutic Area

9. South America Small Molecule Innovator CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Stage Type
    • 9.2.3. By Customer Type
    • 9.2.4. By Therapeutic Area
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Small Molecule Innovator CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Stage Type
        • 9.3.1.2.3. By Customer Type
        • 9.3.1.2.4. By Therapeutic Area
    • 9.3.2. Argentina Small Molecule Innovator CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Stage Type
        • 9.3.2.2.3. By Customer Type
        • 9.3.2.2.4. By Therapeutic Area
    • 9.3.3. Colombia Small Molecule Innovator CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Stage Type
        • 9.3.3.2.3. By Customer Type
        • 9.3.3.2.4. By Therapeutic Area

10. Middle East and Africa Small Molecule Innovator CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Stage Type
    • 10.2.3. By Customer Type
    • 10.2.4. By Therapeutic Area
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Small Molecule Innovator CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Stage Type
        • 10.3.1.2.3. By Customer Type
        • 10.3.1.2.4. By Therapeutic Area
    • 10.3.2. Saudi Arabia Small Molecule Innovator CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Stage Type
        • 10.3.2.2.3. By Customer Type
        • 10.3.2.2.4. By Therapeutic Area
    • 10.3.3. South Africa Small Molecule Innovator CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Stage Type
        • 10.3.3.2.3. By Customer Type
        • 10.3.3.2.4. By Therapeutic Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Clinical Trial Analysis

  • 13.1. Ongoing Clinical Trials
  • 13.2. Completed Clinical Trials
  • 13.3. Terminated Clinical Trials
  • 13.4. Breakdown of Pipeline, By Development Phase
  • 13.5. Breakdown of Pipeline, By Status
  • 13.6. Breakdown of Pipeline, By Study Type
  • 13.7. Breakdown of Pipeline, By Region
  • 13.8. Clinical Trials Heat Map

14. Competitive Landscape

  • 14.1. Lonza Group AG
  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As Reported)
  • 14.5. Recent Developments
  • 14.6. Key Personnel Details
  • 14.7. SWOT Analysis
  • 14.2. Thermo Fisher Scientific Inc
  • 14.3. Cambrex Corporation
  • 14.4. Catalent, Inc
  • 14.5. Siegfried Holding AG
  • 14.6. Recipharm AB
  • 14.7. Corden Pharma GmbH
  • 14.8. Boehringer Ingelheim GmbH
  • 14.9. Piramal Pharma Solutions
  • 14.10. LABCORP HOLDINGS INC.

15. Strategic Recommendations

16. About Us & Disclaimer